Walking Fish Therapeutics Launches with $50 Million in Series A Financing to Accelerate Development of B Cell Therapies for Multiple Diseases

14 Sep, 2021

Walking Fish Therapeutics Launches with $50 Million in Series A Financing to Accelerate Development of B Cell Therapies for Multiple Diseases
Photo by Neven Krcmarek on Unsplash

– Walking Fish Therapeutics, a leader in B cell engineering, announced the close of $50M Series A financing— led by Emerson Collective, Illumina Ventures and Quan Capital— to develop B cell therapeutics for oncology, rare disease, regenerative medicine, autoimmune disease, and recombinant antibody production.
– Walking Fish Therapeutics has made critical advances in developing a platform to harness B cells’ capability to activate the immune system in the treatment of cancer, and to serve as in vivo protein factories that produce replacement proteins for deficiency diseases, regenerative proteins, and engineered antibodies.

Biotechnology Life Science North America
Crunchbase icon

Content report

The following text will be sent to our editors: